Tnf Pharmaceuticals, INC
Market Movers (8-K)
Q/C Technologies, Inc. has terminated its technology license agreement and is now fully concentrating its efforts on its optical processing unit initiative for AI inference.
Q/C Technologies, Inc. has dismissed its independent auditor, Stephano Slack LLC, and appointed Grassi & Co., CPAs, P.C., following prior audit reports that raised substantial doubt about the company's ability to continue as a going concern.
Worse than expected
Q/C Technologies, Inc. announced the appointment of AI systems leader Chelsea Voss to its Board of Directors and a related consulting agreement.
Q/C Technologies, Inc. announced a consulting agreement with Ocean Avenue Holdings LLC, an entity affiliated with Martin Shkreli, who will serve as a Strategic Advisor.
Capital raise
Q/C Technologies, Inc. stockholders approved an increase in its equity incentive plan, a significant common stock issuance, and a potential reverse stock split.
Delay expected
Worse than expected
Capital raise
Q/C Technologies, Inc. filed an amended 8-K to disclose previously omitted Restricted Stock Unit grants totaling 225,000 RSUs to its directors and officers.
Quarterly Earnings (10-Q)
Q/C Technologies, formerly TNF Pharmaceuticals, has pivoted its business strategy to energy-efficient blockchain and high-performance computing, securing new capital and acquiring an exclusive license for laser processing units.
Capital raise
TNF Pharmaceuticals, Inc. reported a significant reduction in net loss for the first half of 2025, driven by non-cash gains, but faces ongoing liquidity challenges and Nasdaq listing compliance issues.
Worse than expected
Delay expected
Capital raise
TNF Pharmaceuticals reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also facing potential delisting from Nasdaq.
Worse than expected
Capital raise
10-Q: TNF Pharmaceuticals Reports Q3 2024 Results, Cites Ongoing Development of MYMD-1 and Supera-CBD
TNF Pharmaceuticals reported its Q3 2024 financial results, highlighting ongoing development of its MYMD-1 and Supera-CBD therapeutic platforms and recent financing activities.
Worse than expected
Delay expected
Capital raise
TNF Pharmaceuticals amended warrants related to recent preferred stock offerings and reported a net loss of $19.3 million for the first half of 2024.
Worse than expected
Capital raise
MyMD Pharmaceuticals reported a net loss of $11 million for Q1 2024 and is facing substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Annual Reports (10-K)
Q/C Technologies, Inc. has filed an amendment to its 2025 Form 10-K to include previously omitted Part III information regarding directors, executive officers, compensation, and related matters.
Delay expected
Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) has filed a description of its capital stock, outlining authorized shares, common and preferred stock details, and the rights associated with each class.
TNF Pharmaceuticals provides a summary of its capital stock, including common and preferred shares, in its latest 10-K filing.
Delay expected
Capital raise
MyMD Pharmaceuticals' recent 10-K filing details its capital structure, including common and preferred stock, warrants, and potential anti-takeover provisions.
Insider Trading (Form 4)
Director Chelsea Sierra Voss acquired 1,753 shares of Q/C Technologies, Inc. (QCLS) common stock at a price of $3.15 per share.
Director Chelsea Voss was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Director Stephen Friscia was granted 50,000 employee stock options in Q/C Technologies, Inc. with an exercise price of $5.00.
Director Billy Joe White was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Chief Medical Officer Mitchell Glass was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Executive Chairman Joshua Silverman acquired 162,162 restricted stock units and 100,000 stock options in Q/C Technologies, Inc.
Proxy Statements (Def-14A)
Q/C Technologies, Inc. calls a Special Meeting to approve a highly dilutive capital raise, an expanded equity incentive plan, and a reverse stock split to maintain Nasdaq listing.
Delay expected
Capital raise
TNF Pharmaceuticals seeks stockholder approval for a reverse stock split to meet Nasdaq listing requirements, an increase in authorized shares for future financing, and an adjustment to the stated value of preferred stock.
Capital raise
DEF: TNF Pharmaceuticals Proposes Reverse Stock Split and Share Increase to Regain Nasdaq Compliance
TNF Pharmaceuticals is seeking stockholder approval for a reverse stock split and an increase in authorized shares to meet Nasdaq listing requirements and enhance financial flexibility.
Capital raise
TNF Pharmaceuticals is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for grant by 2,259,060.
DEF 14A: MyMD Pharmaceuticals Seeks Stockholder Approval for Share Issuance and Increase in Authorized Shares
MyMD Pharmaceuticals is holding a special meeting to seek stockholder approval for issuing shares related to recent financing agreements and to increase the number of authorized shares of common stock.
Worse than expected
Capital raise
Schedule 13D - Activist Investments
PharmaCyte Biotech filed an amended Schedule 13D showing 74% beneficial ownership of Q/C Technologies via preferred stock, warrants, and recent $3M financing with anti-dilution protections.
Capital raise